# BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

> **NCT07679919** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Luminary Therapeutics** · enrollment: 27 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Hairy Cell Leukemia
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** LMY-922

## Key facts

- **NCT ID:** NCT07679919
- **Lead sponsor:** Luminary Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07679919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07679919, "BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07679919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*